HOLX - Hologic wins expanded Medicare coverage for Breast Cancer Index test

Hologic (HOLX) announced that its subsidiary, Biotheranostics has received the broader Medicare coverage for the Breast Cancer Index test under an expanded Medicare Local Coverage Determination.Previously, Medicare-covered the test only for patients with node-negative, non-relapsed, estrogen receptor ((ER)) and/or progesterone receptor ((PR)) positive, HER2 negative breast cancer.The revised coverage includes the post-menopausal women diagnosed with early-stage node-positive (one to three axillary lymph nodes) breast cancer.According to data published by the National Cancer Institute, an estimated ~15% of early-stage, HR+ breast cancers were node-positive in 2021.Therefore, the expanded coverage will make the test available for ~25K more women every year, the company said.In February, Hologic completed the acquisition of the test’s developer Biotheranostics in a deal valued at ~$232M.

For further details see:

Hologic wins expanded Medicare coverage for Breast Cancer Index test